Targeting IL13Ralpha2 using anti‐IL13Ralpha2 CAR‐T cells in patients with leptomeningeal disease from glioblastoma, ependymoma, or medulloblastoma is ongoing in a phase I clinical trial investigating the potential side effects that might be associated with such therapy, as well as the ability of IL13Ralpha2‐CAR‐T cells to destroy brain tumor cells in these patients (NCT04661384). The gene discussed is IL13RA2; the disease is brain neoplasm.